Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
The portfolio for Istituto Oncologico Veneto Iov-Irccs currently shows 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This activity is distributed across a single distinct examiner and a sole distinct art unit, indicating a highly concentrated prosecution focus. The busiest examiner for this portfolio is LI, BAO Q, who is responsible for 1 pending office action.
Because the portfolio involves only a single distinct examiner, the prosecution strategy is entirely dependent on the specific tendencies of LI, BAO Q. Practitioners should note that the current workload in the Biotechnology & Pharmaceuticals space for this entity is limited to this singular point of contact. With only a sole distinct art unit involved, there is no internal variety in examination environments or procedural standards to compare against. This concentration suggests that the applicant's current success in this technology area hinges on the outcomes of a single negotiation. The lack of multiple examiners means there is no opportunity to benchmark examiner behavior across different applications within the same portfolio.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LI, BAO Q | 1 | 75.4% | +26.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| Art Unit | Apps |
|---|---|
| 1671 | 1 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial